Gynecomastia – On Testosterone Ep 2

Gynecomastia is described as benign growth of breast glandular tissue in men, often driven by hormone imbalance. The speaker says any clinician caring for men on testosterone must understand this complication deeply. He notes that adolescent boys can experience transient gynecomastia during puberty, which often resolves over time. Many adult patients report that puberty related breast changes never fully disappeared before therapy began. He explains that testosterone can convert through aromatization to estrogen, which can aggravate breast tissue growth. Because men use injections, gels, or pellets, he emphasizes that delivery method may change symptom intensity. His overall framing is practical: understand baseline risk before assuming testosterone is the only cause.

He then stresses that history matters because many conditions and medications can worsen gynecomastia. He lists hyperthyroidism, obesity, liver disease, and kidney disease as important contributors to evaluate carefully. He also highlights medication triggers, including finasteride, dutasteride, and spironolactone, as classic examples. Additional drugs such as diazepam and cimetidine are mentioned as less obvious contributors in some situations. He describes two presentations, including a tender burning sensation and a lumpier mass effect in breast tissue. Because causes are multifactorial, he urges clinicians to consider genes, exposures, and overall medical context. The goal is to identify reversible drivers before escalating to aggressive hormonal add on therapy.

When moving from history to testing, he recommends total and free testosterone using accurate lab methodology. He emphasizes ultra sensitive estradiol testing, warning that total estrogen can be misleading or contaminated. For long term management, he argues that symptoms and careful dosing matter more than repeated estrogen checks. He explains that micro dosing and adjusting injection frequency can prevent gynecomastia for many men. Systemic anti estrogens, including aromatase inhibitors and tamoxifen, are framed as last resort options. He warns these drugs may worsen mood, libido, and cardiovascular risk, especially with prolonged use. He closes by urging personalized care, because long term safety requires balancing benefits and risks.